CALCIMEDICA INC

CALCNASDAQ

🏆 #3625 by market capEarnings Aug 18US Equity

$664.69▼ $0.47 (−0.07%)

Simulated price

1h—

24h▼ 0.1%

7d—

14d—

30d—

1y—

🏦Market Cap

$20M

Small Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

—

Otter Score

Weak

No chart data available for CALC.

Trading Snapshot

Day Range: $660.86 – $672.75
52-Week Range: $0.46 – $7.20
Volume: $2.33B
Avg Volume: $2.66B
Shares Outstanding: 30.7M
Next Earnings: Oct 23, 2026

Fundamentals Snapshot

Annual Revenue: $1M
Last Q Revenue: $356,706
P/E Ratio: —
P/S Ratio: —
EPS (TTM): $-1.29
Dividend Yield: —

Why Investors Own CALC

✓High-growth profile — revenue up +2.2% YoY with expanding US Equity exposure.
✓Healthy economics — 36% gross margin and 10% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$1M▲ +6.0% YoY

Gross Margin (TTM)

36.1%▲ +1.7% YoY

Operating Income (TTM)

$444,460▲ +6.0% YoY

Free Cash Flow (TTM)

$134,307▲ +6.0% YoY

About CALCIMEDICA INC

CalciMedica, Inc., a clinical-stage biotechnology company headquartered in La Jolla, California, is focused on creating treatments for life-threatening inflammatory diseases that currently lack adequate therapies. The company's proprietary approach involves blocking calcium release-activated (CRAC) channels, a mechanism designed to modulate the immune system and protect against cellular and tissue damage in these severe conditions. Their primary experimental drug, Auxora, is an intravenously administered, proprietary CRAC channel inhibitor being developed for the treatment of acute pancreatitis, including its asparaginase-associated form, and acute kidney injury.

🦦